# Secretin Enhanced MRCP for Evaluation of the Known or Suspected Intraductal Papillary Mucinous Neoplasms of the Pancreas

> **NCT00621556** · PHASE1 · TERMINATED · sponsor: **Massachusetts General Hospital** · enrollment: 2 (actual)

## Conditions studied

- Intraductal Papillary Mucinous Neoplasms

## Interventions

- **DRUG:** RG1068 (Synthetic Human Secretin)

## Key facts

- **NCT ID:** NCT00621556
- **Lead sponsor:** Massachusetts General Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2008-02
- **Primary completion:** 2008-12
- **Final completion:** 2008-12
- **Target enrollment:** 2 (ACTUAL)
- **Why stopped:** Poor patient enrollment due to logistical issues
- **Last updated:** 2009-01-29


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00621556

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00621556, "Secretin Enhanced MRCP for Evaluation of the Known or Suspected Intraductal Papillary Mucinous Neoplasms of the Pancreas". Retrieved via AI Analytics 2026-07-26 from https://api.ai-analytics.org/clinical/NCT00621556. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*